

FORM PTC-1449
(Modified)

12/03/99

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: OPHD-03282

Serial No.: 09/095,536

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: John A. Kink

Filing Date: 06/10/98

Group Art Unit: 1646

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
FH	1	5,654,407	08/05/97	Boyle <i>et al.</i>	530	388.15	05/05/95
	2	5,436,154	07/25/95	Barbanti <i>et al.</i>	435	240.27	12/13/91
	3	5,385,901	01/31/95	Kaplan <i>et al.</i>	514	231.5	10/02/92
	4	4,870,163	09/26/89	Rubin <i>et al.</i>	530	413	08/29/85
	5	5,656,272	08/12/97	Le <i>et al.</i>	424	133.1	02/04/94

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
FH	6	WO 96/33204	24.10.96	PCT	X	X		

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

FH	7	Machiedo <i>et al.</i> , "Patterns of Mortality in a Surgical Intensive Care Unit," <i>Surg. Gyn. & Obstet.</i> 152:757-759 (1981)
	8	Morris <i>et al.</i> , "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J-5)," <i>Am. J. Vet. Res.</i> 47:2554-2565 (1986)
	9	Hoffman <i>et al.</i> , "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," <i>J. Vet. Int. Med.</i> 6:89-95 (1992)
	10	Wolff, "Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock," <i>New Eng. J. Med.</i> 324:486-488 (1991)
	11	K.A. Schulman <i>et al.</i> , "Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis," <i>JAMA</i> 266:3466-3471 (1991)
	12	K. Ohlsson <i>et al.</i> , "Interleukin-1 receptor antagonist reduces mortality from endotoxin shock," <i>Nature</i> 348:550-552 (1990)
	13	R.C. Bone, "The Pathogenesis of Sepsis," <i>Ann. Intern. Med.</i> 115:457-469 (1991)
	14	K.J. Tracey <i>et al.</i> , "Shock and Tissue Injury Induced by Recombinant Human Cachectin," <i>Science</i> 234:470-474 (1986)
	15	A. Tewari <i>et al.</i> , "Preliminary report: effects of interleukin-1 on platelet counts," <i>Lancet</i> 336:712-714 (1990)
	16	S.M. Opal <i>et al.</i> , "Efficacy of a Monoclonal Antibody Directed against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. Infect. Dis.</i> 161:1148-1152 (1990)
	17	Polson <i>et al.</i> , "Antibodies to Proteins from Yolk of Immunized Hens," <i>Immunol. Comm.</i> , 9:495 (1980)
	18	C. Galanos <i>et al.</i> , "Galactosamine-induced sensitization to the lethal effects of endotoxin," <i>Proc. Natl. Acad. Sci. USA</i> 76:5939-5943 (1979)
	19	J. Rothe <i>et al.</i> , "Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by <i>Listeria monocytogenes</i> ," <i>Nature</i> 364:798-802 (1993)
	20	S.Q. DeJoy <i>et al.</i> , "Effect of CL 184,005, a Platelet-Activating Factor Antagonist in a Murine Model of <i>Staphylococcus aureus</i> -Induced Gram-Positive Sepsis," <i>J. Infect. Dis.</i> 169:150-156 (1994)
	20	Opal <i>et al.</i> , "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock," <i>J. of Infectious Diseases</i> 173:1415-1421 (1996)
	20	Russell <i>et al.</i> , "Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function," <i>J. of Infectious Diseases</i> 171:1528-1538 (1995)
	23	Plevy <i>et al.</i> , "A Role for TNF- α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," <i>J. of Immunology</i> 159:6277-6282 (1997)
	24	Van Dulleman <i>et al.</i> , "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> 109:129-138 (1995)
	25	Targan <i>et al.</i> , "A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease," <i>NEJM</i> , 337:1029-1035 (1997)

Examiner:

Fue 1/2/99

Date Considered:

12/17/99

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: OPHD-03282	Serial No.: 09/095,536
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: John A. Kink	
(37 CFR § 1.98(b))				Filing Date: 06/10/98	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
FH	26	Elliott <i>et al.</i> , "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> 344:1105-1110 (1994)			
27	Elliott <i>et al.</i> , "Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis," <i>Lancet</i> 344:1125-1127 (1994)				
28	Kojouharoff <i>et al.</i> , "Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice," <i>Clin Exp Immunol</i> 107:353-358 (1997)				
29	Olson <i>et al.</i> , "Antiserum to Tumor Necrosis Factor and Failure to Prevent Murine Colitis," <i>J Ped Gastroenterology Nutrition</i> 21:410-418 (1995)				
30	Zacharchuk <i>et al.</i> , "Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor," <i>PNAS USA</i> 80:6341-6345 (1983)				
31	Zacharchuk, Charles Michael, "A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization," <i>Dissertation Abstract</i>				
32	Pennica <i>et al.</i> , "Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> 312:724-729 (1984)				
33	Ruff, Michael Roland, "Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor," <i>Dissertation Abstract</i>				
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
Examiner: <i>Gene H. [Signature]</i>		Date Considered: 12/17/95			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: OPHD-03282

Serial No.: 09/095,536

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: John A. Kink

Filing Date: 06/10/98

Group Art Unit: 1646

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Subclass	Filing Date	
ES	1	5,420,253	5/30/95	Emery et al.	530	423	9/09/93

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Fit	2	Doherty <i>et al.</i> , "Evidence for IFN- γ as a Mediator of the Lethality of Endotoxin and Tumor Necrosis Factor- α ," <i>J. Immunology</i> 149(5):1666-1670 (1992)
	3	Manthey <i>et al.</i> , "The role of cytokines in host responses to endotoxin," <i>Reviews in Medical Microbiology</i> 3(2):72-79 (1992)
↓	4	Starnes <i>et al.</i> , "Anti-IL-6 Monoclonal Antibodies Protect Against Lethal Escherichia coli Infection and Lethal Tumor Necrosis Factor- α challenge in mice," <i>J. of Immun.</i> 145(12):4185-4191 (1990)
	5	
	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	23	
	19	
	23	
	23	
	22	
	23	
	23	
	25	

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.